Treatment of Patients with Multiple Brain Metastases by Isolated Radiosurgery: Toxicity and Survival

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2023 Nov 16

PMID 37970107

Authors

Andre Vinicius de Camargo

Marcos Duarte de Mattos

Murilo Kenji Kawasaki

Danilo Nascimento Salviano Gomes

Allisson Bruno Barcelos Borges

Vinicius de Lima Vazquez

Raphael L C Araujo

Affiliations

Soon will be listed here.

Abstract

Background: Radiosurgery for multiple brain metastases has been more reported recently without using whole-brain radiotherapy. Nevertheless, the sparsity of the data still claims more information about toxicity and survival and their association with both dosimetric and geometric aspects of this treatment.

Aim: To assess the toxicity and survival outcome of radiosurgery in patients with multiple (four or more lesions) brain metastases.

Methods: In a single institution, data were collected retrospectively from patients who underwent radiosurgery to treat brain metastases from diverse primary sites. Patients with 4-21 brain metastases were treated with a single fraction with a dose of 18 Gy or 20 Gy. The clinical variables collected were relevant to toxicity, survival, treatment response, planning, and dosimetric variables. The Spearman's rank correlation coefficients, Mann-Whitney test, Kruskal-Wallis test, and Log-rank test were used according to the type of variable and outcomes.

Results: From August 2017 to February 2020, 55 patients were evaluated. Headache was the most common complaint (38.2%). The median overall survival (OS) for patients with karnofsky performance status (KPS) > 70 was 8.9 mo, and this was 3.6 mo for those with KPS ≤ 70 ( = 0.047). Patients with treated lesions had a median progression-free survival of 7.6 mo. There were no differences in OS (19.7 9.5 mo) or progression-free survival (10.6 6.3 mo) based on prior irradiation. There was no correlation found between reported toxicities and planning, dosimetric, and geometric variables, implying that no additional significant toxicity risks appear to be added to the treatment of multiple (four or more) lesions.

Conclusion: No associations were found between the evaluated toxicities and the planning dosimetric parameters, and no differences in survival rates were detected based on previous treatment status.

References

Chang E, Wefel J, Hess K, Allen P, Lang F, Kornguth D . Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10(11):1037-44. DOI: 10.1016/S1470-2045(09)70263-3. View

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K . Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295(21):2483-91. DOI: 10.1001/jama.295.21.2483. View

Reali A, Allis S, Girardi A, Verna R, Bianco L, Ruo Redda M . Is Karnofsky Performance Status Correlate with Better Overall Survival in Palliative Conformal Whole Brain Radiotherapy? Our Experience. Indian J Palliat Care. 2015; 21(3):311-6. PMC: 4617039. DOI: 10.4103/0973-1075.164891. View

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View

de Camargo A, Cao M, Silva D, de Araujo R . Evaluation of the correlation between dosimetric, geometric, and technical parameters of radiosurgery planning for multiple brain metastases. J Appl Clin Med Phys. 2021; 22(8):83-92. PMC: 8364278. DOI: 10.1002/acm2.13326. View

Selvan K, Padma G, Revathy M, Nambi Raj N, Senthilnathan K, Babu P . Dosimetric Effect of Rotational Setup Errors in Single-Isocenter Volumetric-Modulated Arc Therapy of Multiple Brain Metastases. J Med Phys. 2019; 44(2):84-90. PMC: 6580820. DOI: 10.4103/jmp.JMP_103_18. View

Sperduto P, Kased N, Roberge D, Xu Z, Shanley R, Luo X . Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011; 30(4):419-25. PMC: 3269967. DOI: 10.1200/JCO.2011.38.0527. View

Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Watanabe S . Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors. J Neurosurg. 2014; 121 Suppl:16-25. DOI: 10.3171/2014.8.GKS141421. View

Nieder C, Andratschke N, Geinitz H, Grosu A . Diagnosis-specific graded prognostic assessment score is valid in patients with brain metastases treated in routine clinical practice in two European countries. Med Sci Monit. 2012; 18(7):CR450-5. PMC: 3560784. DOI: 10.12659/msm.883213. View

10.

Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J . Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4):387-95. DOI: 10.1016/S1470-2045(14)70061-0. View

11.

Roper J, Chanyavanich V, Betzel G, Switchenko J, Dhabaan A . Single-Isocenter Multiple-Target Stereotactic Radiosurgery: Risk of Compromised Coverage. Int J Radiat Oncol Biol Phys. 2015; 93(3):540-6. PMC: 4610743. DOI: 10.1016/j.ijrobp.2015.07.2262. View

12.

Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M . Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015; 91(4):710-7. DOI: 10.1016/j.ijrobp.2014.10.024. View

13.

Huh H, Sub Y, Oh J, Kim Y, Lee J, Kim H . Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination. Mol Cancer. 2023; 22(1):63. PMC: 10061822. DOI: 10.1186/s12943-023-01753-7. View

14.

Narayanasamy G, Smith A, Van Meter E, McGarry R, Molloy J . Total target volume is a better predictor of whole brain dose from gamma stereotactic radiosurgery than the number, shape, or location of the lesions. Med Phys. 2013; 40(9):091714. PMC: 4108722. DOI: 10.1118/1.4818825. View

15.

Nagtegaal S, Claes A, Suijkerbuijk K, Schramel F, Snijders T, Verhoeff J . Comparing survival predicted by the diagnosis-specific Graded Prognostic Assessment (DS-GPA) to actual survival in patients with 1-10 brain metastases treated with stereotactic radiosurgery. Radiother Oncol. 2019; 138:173-179. DOI: 10.1016/j.radonc.2019.06.033. View

16.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

17.

Minniti G, Clarke E, Lanzetta G, Osti M, Trasimeni G, Bozzao A . Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011; 6:48. PMC: 3108308. DOI: 10.1186/1748-717X-6-48. View

18.

Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J . The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer. Adv Sci (Weinh). 2022; 10(5):e2203699. PMC: 9929130. DOI: 10.1002/advs.202203699. View

19.

Brown P, Jaeckle K, Ballman K, Farace E, Cerhan J, Anderson S . Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016; 316(4):401-409. PMC: 5313044. DOI: 10.1001/jama.2016.9839. View

20.

Fokas E, Henzel M, Surber G, Kleinert G, Hamm K, Engenhart-Cabillic R . Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases. J Neurooncol. 2012; 109(1):91-8. DOI: 10.1007/s11060-012-0868-6. View